Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Ursula Buchholz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $1,290,899 — We previously performed codon-pair deoptimization (CPD) of various open reading frames (ORFs) of RSV. This is done by rearranging codons of RSV open reading frames using computer algorithms and de novo gene synthesis to increase the content of normally underrepresented codon-pairs without changing a…
Nicolas Wentzensen · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · 2023 · $676,491 — The following research projects are etiologic and human population based and all have various molecular components:SUCCEED directed by Dr. Wentzensen is a cross-sectional study among women referred for abnormal cevrical cancer screening results focused on the identification of biomarkers of risk at …
ALAN REIN · DIVISION OF BASIC SCIENCES - NCI · 2023 · $662,874 — There appear to be several different modes of interaction between retroviral proteins and nucleic acids, each with important functional consequences for viral replication. First, an exquisitely specific recognition by the Gag polyprotein (the structural protein of the virus particle) selects the vir…
Daniel Cesar Douek · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2023 · $2,424,710 — The Genome Analysis Core (TGAC), within the Human Immunology Section, was set up in 2014 to fulfill many of the specialist sequencing needs of the Vaccine Research Center (VRC). Currently, the VRC is designing, producing and testing candidate immunogens aimed at eliciting broadly neutralizing antibo…
Jordan L Meier · DIVISION OF BASIC SCIENCES - NCI · 2023 · $2,119,522 — The goal of this project is to characterize and control novel modification-based regulatory mechanisms that drive altered gene activity in cancer. The majority of our initial efforts in this area have focused on the study of protein and nucleic acid acetylation. Using a suite of novel chemical biolo…
BALI PULENDRAN · STANFORD UNIVERSITY · 2023 · $512,494 — ABSTRACT – Project 1 In the current proposal, we will use systems biological approaches to address two fundamental issues in vaccinology. The first issue concerns the immunology of COVID-19 vaccines, which utilize novel platforms (mRNA) or adjuvants (Matrix M used in the Novavax vaccine). The second…
Mark Morris Davis · STANFORD UNIVERSITY · 2023 · $379,046 — ABSTRACT – Project 2 The goal of Project 2 is to assess T cell responses in the context of proposed studies of: (i) COVID-19 vaccines that utilize novel platforms (mRNA) or adjuvants (Matrix M used in the Novavax vaccine) and (ii) Humans given broad spectrum antibiotics that disrupt their microbiome…
Purveshkumar Khatri · STANFORD UNIVERSITY · 2023 · $317,322 — ABSTRACT – Data Management and Analysis Core. Identifying the biological features of the human immune response that correlate with and predict the development of an effective immune response to vaccination is an overarching goal of this U19 consortium. The Data Management and Analysis Core (DMAC) in…
Corey Casper · FRED HUTCHINSON CANCER CENTER · 2023 · $375,190 — Abstract Scientific Core One has the responsibility of creating, validating, and providing R&D-grade HIV-Env immunogen-expressing self-amplifying RNAs (saRNAs) complexed with the nanostructured lipid carrier (NLC) delivery vehicle to project leads at Fred Hutchinson Cancer Research Center for in viv…
GARRY P NOLAN · STANFORD UNIVERSITY · 2023 · $279,317 — PROJECT SUMMARY New technologies such as mass cytometry have greatly expanded our ability to deepen our understanding of the complexity of lymphocytes and related populations. The Stanford CCHI group has been particularly attuned to the potential in following the lead of the Nolan lab in exploiting …
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2023 · $1,498,202 — Project Summary Administrative Core This Phase II COBRE will continue our center’s work to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approaches for unde…
Sallie R. Permar · WEILL MEDICAL COLL OF CORNELL UNIV · 2023 · $480,199 — ABSTRACT – Nonhuman Primate Core (NHP Core/ Core 1) The end of the HIV/AIDS epidemic will be achievable only when an effective vaccine regimen can achieve long-term protective immunity, similar to that of vaccines that have nearly eliminated other global pathogens. HIV acquisition risk begins in ute…
JOSEPH M FOX · UNIVERSITY OF DELAWARE · 2023 · $256,851 — Project Summary Administrative Core This Phase II COBRE will continue our center’s work to develop molecular approaches for probing biology, to discover and apply new chemical biology tools for the study of biological pathways associated with disease, and to develop computational approaches for unde…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2023 · $372,511 — The Administrative Core A, led by Dr. Richard Wyatt, will administer support for Projects 1 and 2 and Cores B and C, under the umbrella of this new HIVRAD proposal. This Core will coordinate an administrative partnership plan to maintain good communications within the HIVRAD working group and rele…
Nir Hacohen · MASSACHUSETTS GENERAL HOSPITAL · 2023 · $148,180 — Project Summary The overall objective of the U19 is to discover the role of the PD-1 pathway in human immunity by studying the effects of therapeutic PD-1 blockade on immune responses to chronic viruses (Project 1) and preventive vaccines (Project 2). To monitor adaptive immune responses in patients…
Matthew Adrian Coleman · LAWRENCE LIVERMORE NATIONAL SECURITY, LLC · 2023 · $385,910 — ABSTRACT Throughout the world Chlamydia trachomatis (Ct) is the most common sexually transmitted bacterial pathogen. In countries with poor sanitary conditions ocular infections with Ct can result in trachoma, the most frequent cause of preventable blindness worldwide. Based on protection and serolo…
Adolfo Garcia-Sastre · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $360,450 — Two years into the COVID-19 pandemic, SARS-CoV-2 infections are still responsible for huge economic losses, lockdowns and stressed health care systems worldwide. Different from the situation early during the pandemic, when the virus started circulating in the human population in the absence of pre-e…
Frederic D Bushman · UNIVERSITY OF PENNSYLVANIA · 2023 · $167,770 — SUMMARY- CORE B (GENOMICS CORE) Core B (Genomics Core) will provide key support to the mVACS team in Clostridioides difficile genome sequence analysis, antigen design, microbiome sequence analysis, routine statistical analysis, and high content data management. Core B will use advanced genomics-base…
Gregory Lee Szeto · SEATTLE CHILDREN'S HOSPITAL · 2023 · $117,223 — HIPC3 Scientific Project 3: Immune response to SARS-CoV-2 natural infection followed by vaccination Abstract This project will characterize the innate and adaptive immune response to SARS-CoV-2 natural infection in the setting of mild disease and follow-on vaccination. We will define signatures corr…
DREW WEISSMAN · UNIVERSITY OF PENNSYLVANIA · 2023 · $301,171 — SUMMARY- PROJECT 1 (VACCINE DEVELOPMENT) Clostridioides difficile is a gram negative spore forming pathogen that causes mild to severe gastrointestinal disorders and death in the elderly, immune compromised individuals and those exposed to systemic antibiotics. Increased recurrence and difficulties …